Xenopat
Xenopat S.L. is a Barcelona-based preclinical oncology services company providing orthotopic Patient-Derived Xenograft (PDX) models (orthoxenografts®) and a 350+ model OrthoXenoBank® to pharmaceutical companies for anticancer drug development and to oncologists and patients for personalized cancer treatment guidance, operating as a spin-off of ICO, IDIBELL, and Bellvitge University Hospital.
- Company typePrivate
- Founded2014
- HeadquartersL'hospitalet De Llobregat, Spain
- Headcount1–10
- GTM typeB2B and B2C
- OfferingServices
What Xenopat does
Xenopat S.L. is a Spanish preclinical oncology services company operating as a spin-off of the Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), and Bellvitge University Hospital (HUB), headquartered in L'Hospitalet de Llobregat, Barcelona. The company specializes in orthotopic Patient-Derived Xenograft (PDX) models branded as "orthoxenografts®," in which a small fragment of a human tumor is implanted in the corresponding organ of immunodeficient mice within 24 hours of surgical removal. These models preserve the histological, genetic, and molecular characteristics of the original tumor and are the basis for two service lines: Advanced Preclinical Services sold to pharmaceutical and biotech clients (including drug response evaluation, MTD studies, co-clinical trials, drug repositioning, and acquired resistance studies) and Personalized Cancer Treatment delivered through oncologists and the Bellvitge hospital network (producing patient-specific drug response reports known as the "antiquimiograma" within 4–8 months). The core technology asset is the OrthoXenoBank®, a proprietary collection of more than 350 characterized orthotopic PDX models spanning colon, lung, breast, ovarian, pancreatic, endometrial, head and neck, liver, and germ cell tumors, including matched chemotherapy-sensitive and resistant pairs.
The company is privately held, organized as a Sociedad Limitada (C.I.F. B66362088), founded in 2014, and operates with 1–10 employees. Revenue is generated through project-based professional services contracts with pharmaceutical companies and direct payments from patients for personalized treatment, with no publicly disclosed pricing; a small prefixed implantation fee applies if a tumor fails to engraft (typical engraftment rates 70–75%). The firm does not operate any self-serve or e-commerce channel, instead relying on direct sales engagement and clinical collaboration through its hospital partner network. Go-to-market is supplemented by an active portfolio of EU-funded research consortia (Horizon 2020, IMI2, Eurostars, MSCA, AGAUR, Doctorados Industriales) that provide non-dilutive funding, scientific credibility, and partner visibility across European oncology research. Xenopat is led by three co-founders: CEO Anna Portela (PhD in Genetics, ESADE MBA), CSO Alberto Villanueva (inventor of the orthoxenograft terminology, 60+ publications), and Chief of Molecular Pathology August Vidal (70+ publications, pathologist at HUB).
Xenopat firmographics
Firmographics- Name
- Xenopat
- Legal name
- Xenopat S.L.
- Website
- https://xenopat.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Xenopat S.L. is a Barcelona-based preclinical oncology services company providing orthotopic Patient-Derived Xenograft (PDX) models (orthoxenografts®) and a 350+ model OrthoXenoBank® to pharmaceutical companies for anticancer drug development and to oncologists and patients for personalized cancer treatment guidance, operating as a spin-off of ICO, IDIBELL, and Bellvitge University Hospital.
- Ownership category
- akta.pro rank
Xenopat industry classification
Industry- Product category
- Preclinical Oncology Research Services
- NAICS
- Medical Laboratories (621511), Other Ambulatory Health Care Services (6219)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)
- akta.pro secondary industries
- Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology) (HLAIALAC), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where Xenopat is headquartered
LocationHeadquarters
- HQ city
- L'hospitalet De Llobregat
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Xenopat business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
Revenue model
- Advanced Preclinical Services: Contract research services offered to pharmaceutical companies and researchers developing new anticancer drugs. Services include: generation of customized cell lines, Maximum Tolerated Dose determination, dosage schedule studies, drug combination optimization, drug response evaluation using clinicopathological standards, gene expression analysis, genetic/epigenetic studies, identification of drug targets/mechanisms of action, generation of customized orthoxenografts, co-clinical paired trials in human and mice, drug repositioning studies, and acquired resistance studies. Revenue is earned through project-based service contracts, likely billed per study or milestone.
- Personalized Cancer Treatment: Direct-to-patient service generating patient-specific orthoxenografts for personalized oncology treatment guidance. The process produces an antiquimiograma (Response Report) recommending optimal therapy. Patients pay for the service, with the process taking 4–8 months from tumor implantation to report delivery. Cryopreservation services for future reimplantation are also offered.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Xenopat product offering
Product offeringCore offering
Xenopat provides preclinical oncology contract research services and personalized cancer treatment guidance built on its proprietary orthotopic Patient-Derived Xenograft (orthoxenograft®) models. Its two main commercial offerings are Advanced Preclinical Services — drug response evaluation, MTD determination, drug combination optimization, gene expression and genetic/epigenetic studies, co-clinical trials, drug repositioning, and acquired resistance studies — sold to pharmaceutical and biotech clients, and Personalized Cancer Treatment — generation of patient-specific orthoxenografts and an Antiquimiograma (Response Report) — sold to oncologists and patients in collaboration with hospital partners. The OrthoXenoBank® of more than 350 characterized orthotopic PDX models is the underlying asset for both lines.
Product overview
Xenopat is a preclinical oncology services company offering two main service areas: Advanced Preclinical Services for drug development researchers and pharmaceutical companies, and Personalized Cancer Treatment for healthcare professionals and patients. The core product is OrthoXenoBank®, a collection of more than 350 orthoxenograft models (orthotopic patient-derived xenografts/PDXs), which are mouse models implanting human tumor fragments in their matching organ of origin. These orthoxenografts maintain histological and genetic characteristics of original tumors and mimic drug response patterns. Services include customized orthoxenograft generation, drug response evaluation, genetic/epigenetic studies, and co-clinical trials. For personalized treatment, the company generates patient-specific orthoxenografts to test drug alternatives and delivers a Response Report (antiquimiograma) guiding treatment selection.
Differentiator
Problem solved
Functional benefit
Brands
- OrthoXenoBank: Collection of orthoxenograft models (orthotopic patient-derived xenografts) for preclinical oncology drug research, comprising over 350 models across multiple tumor types.
- Orthoxenografts
- Antiquimiograma
Products and services
- Advanced Preclinical Services Contract research partnership offering pharmaceutical companies, biotech firms, and academic researchers the most innovative tools for oncological drug development, including access to the OrthoXenoBank®, customized orthoxenograft generation, drug response evaluation, Maximum Tolerated Dose determination, drug combination optimization, dosage schedule studies, gene expression analysis, genetic and epigenetic studies, identification of drug targets/mechanisms of action, co-clinical paired trials in mice and humans, drug repositioning studies, and acquired resistance studies.
- Personalized Cancer Treatment Healthcare service that generates orthoxenografts from a small fragment of a patient's tumor, tests multiple drugs on colony subpopulations, and produces an Antiquimiograma (Response Report) recommending the most appropriate therapy. Delivered to oncologists and patients (particularly those with aggressive, refractory, or relapsing tumors) in coordination with hospital partners such as Bellvitge University Hospital, with optional cryopreservation for future reimplantation in case of relapse.
- OrthoXenoBank® A collection of more than 350 orthotopic PDX models (orthoxenografts®) representing the most frequent histological subtypes of tumors in colon, lungs, breasts, ovaries, pancreas, endometrium, head and neck, liver, and germ cells. All models are classified by histological subtype and genetically characterized for the most relevant mutations, with some carrying acquired resistance to standard chemotherapy and others being endogenous refractory tumors; the bank also contains matched chemotherapy-sensitive and -resistant orthoxenograft pairs generated through repeated treatment exposure in vivo. Licensed/provided to pharmaceutical and biotech clients as part of Advanced Preclinical Services engagements.
- Orthoxenografts® Mouse models in which a small piece of human tumor is implanted orthotopically in the same organ of origin (also known as Patient-Derived Orthotopic Xenografts, PDXs/PDOXs). Xenopat develops and supplies these models to maintain the histological, genetic, and molecular characteristics of the original tumor and to mimic drug response patterns, including generation of customized orthoxenografts for specific client projects.
- In Vitro Pre-Screening Platform Preclinical drug-screening service in development that establishes cell lines derived from patient-derived xenografts (PDXs) for in vitro drug testing, designed to enhance the efficiency of preclinical oncology drug research, reduce animal use, and maintain the predictive power of PDX models in line with the 3Rs principle and recent regulatory changes.
Quantifiable outcome
- Engraftment rates of 70–75% depending on tumor type and fragment size
- +2 more outcomes
Companies that use Xenopat
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Xenopat technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Xenopat partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered minor and core.
- EVEREST (Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics)minorEU Horizon-funded MSCA Staff Exchanges 2023 project (Jan 2025–Dec 2028) focused on standardizing extracellular vesicle isolation and characterization for biomarkers and drug delivery vehicles. Xenopat is a consortium member alongside 8+ institutions.
- In Vitro Pre-Screening Platform (Doctorados Industriales, Ministerio de Ciencia)minorSpanish Ministry of Science funded doctoral industrial project (Oct 2024–Oct 2028) developing an in vitro pre-screening service using PDX-derived cell lines to reduce animal use in preclinical oncology while maintaining predictive power.
- In Vitro PDX Cell Lines (Doctorat Industrial AGAUR)minorCatalan AGAUR-funded doctoral industrial project (Oct 2024–Oct 2027) establishing cell lines from patient-derived xenografts for in vitro drug screening, reducing animal use in line with the 3Rs principle.
- GlioPep (Eurostars-Eureka, CDTI)minorEurostars-Eureka funded project (Mar 2023–Mar 2026) developing a next-generation peptide drug conjugate as a novel tumor-specific treatment for glioblastoma. Co-funded by EU HorizonEurope and CDTI.
- DEFIT-CRC (Tecniospring, ACCIÓ)minorACCIÓ Tecniospring talent program project (Mar 2022–Oct 2024) developing a T14 inhibitor for treatment of colorectal cancer, hiring qualified R&D personnel.
- PERSIST-SEQ (Innovative Medicines Initiative 2)minorIMI2 and EFPIA-funded project (Jul 2021–Jun 2026) developing a standardized single-cell workflow to study cancer treatment resistance, characterizing 5 million cells in lung, colorectal, and breast cancer models.
- ColoSelect (Eurostars-2, CDTI)minorEurostars-2 funded project (Apr 2021–Jan 2024) developing BOT1700, a theranostic nanobody targeting PDGF-beta receptor for PET imaging and targeted radiotherapy in CMS4 colorectal cancer.
- CRYSTAL3 (EU Horizon 2020 MSCA RISE)minorEU Horizon 2020 MSCA RISE consortium (Jan 2021–Dec 2024) with 12 members in 8 countries, led by University College Dublin, investigating cysteinyl leukotriene signaling in cancer and cardiovascular disease. €887,800 funding.
- nOVAB (Eurostars)minorEurostars-funded project (Oct 2019–Oct 2022) developing a first-in-class monoclonal antibody therapy targeting a novel tumor-specific epitope for ovarian cancer treatment.
- EpiPharm (European Research Council Proof of Concept)minorERC Proof of Concept Grant (Feb 2017–Jul 2018) developing a DNA methylation kit targeting non-coding RNA regions to support treatment decisions in Cancer of Unknown Primary (CUP).
- 3D NEONET (EU Research Consortium)minorEU research consortium (Jan 2017–Jun 2022) bringing together 18 institutions in 7 countries to accelerate therapeutic development for oncology and ophthalmology.
- Catalan Institute of Oncology (ICO)coreXenopat is a spin-off company of the Catalan Institute of Oncology (ICO). The Drug Resistance Group at ICO-IDIBELL, led by co-founder Alberto Villanueva, serves as the principal investigator group, providing institutional research backing and access to clinical specimens.
- Bellvitge Biomedical Research Institute (IDIBELL)coreXenopat is a spin-off of the Bellvitge Biomedical Research Institute (IDIBELL). The institute provides research infrastructure, talent, and clinical collaboration for Xenopat's orthoxenograft development activities.
- Bellvitge University Hospital (HUB)coreXenopat is a spin-off of the Bellvitge University Hospital (HUB). Co-founder August Vidal is a pathologist at HUB. The hospital provides clinical specimens and pathology expertise essential for orthoxenograft characterization.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Xenopat competitors and assessment
Company assessmentEmerging players
- Taconic Biosciences: Provider of genetically engineered mouse models and related preclinical services with growing oncology and PDX offerings. Comparable but broader in mouse model portfolio than Xenopat's orthotopic specialty.
- Caris Life Sciences: Precision oncology company offering molecular profiling and AI-driven treatment recommendations for cancer patients. Adjacent competitor in personalized oncology treatment selection, though using molecular rather than in vivo functional testing.
- Tempus: AI-driven precision medicine company providing molecular profiling, multi-omic data, and treatment decision support for oncology. Adjacent player in evidence-based personalized oncology treatment guidance.
Direct peers
- Oncodesign: French preclinical CRO specializing in oncology drug discovery and translational models, including patient-derived xenografts and pharmacological profiling. Comparable European peer with similar pharma customer base and service mix.
- Champions Oncology: US-based oncology CRO specializing in patient-derived xenograft (PDX) models, tumor organoids, and personalized oncology services. Directly competes with Xenopat in offering PDX-based preclinical and translational services to pharma and patients.
- Experimental Pharmacology and Oncology (EPO): German-based preclinical oncology CRO offering PDX models, patient-derived tumor models, and in vivo pharmacology services to pharma clients. Comparable specialty European CRO in the same niche.
- Crown Bioscience: Global preclinical and translational CRO with one of the largest collections of PDX models (HuPrime®) and oncology drug development services. Closest large-scale direct competitor to Xenopat's OrthoXenoBank® offering.
- Xentech: French preclinical CRO focused on oncology and immuno-oncology using patient-derived tumor models, including PDX and ex vivo approaches. Comparable specialty CRO serving pharma clients with translational oncology services.
Broad incumbents
- The Jackson Laboratory: Large nonprofit biomedical research institution providing PDX model development, mouse model distribution, and preclinical oncology services. Broader incumbent with overlapping translational model capabilities but much wider scope.
- Charles River Laboratories: Large global CRO with significant oncology preclinical services including PDX and tumor model offerings. Broad incumbent whose oncology segment overlaps with Xenopat's pharma services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Xenopat social profiles
Digital presenceXenopat financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xenopat leadership team
Management profileNumber of profiles
Profiles3 records
Xenopat funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xenopat M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xenopat
What does Xenopat do?
Xenopat provides preclinical oncology contract research services and personalized cancer treatment guidance built on its proprietary orthotopic Patient-Derived Xenograft (orthoxenograft®) models. Its two main commercial offerings are Advanced Preclinical Services — drug response evaluation, MTD determination, drug combination optimization, gene expression and genetic/epigenetic studies, co-clinical trials, drug repositioning, and acquired resistance studies — sold to pharmaceutical and biotech clients, and Personalized Cancer Treatment — generation of patient-specific orthoxenografts and an Antiquimiograma (Response Report) — sold to oncologists and patients in collaboration with hospital partners. The OrthoXenoBank® of more than 350 characterized orthotopic PDX models is the underlying asset for both lines.
Is Xenopat a public or private company?
Xenopat is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Xenopat founded?
Xenopat was founded in 2014. It employs 1 to 10 people.
Where is Xenopat based?
Xenopat is headquartered in L'hospitalet De Llobregat, Spain, in the Europe region.
How does Xenopat make money?
Two revenue lines are on record. Advanced Preclinical Services are the primary driver. The others are personalized Cancer Treatment.
Who are Xenopat's main competitors?
Emerging players on record are Taconic Biosciences, Caris Life Sciences and Tempus. Direct peers are Oncodesign, Champions Oncology, Experimental Pharmacology and Oncology (EPO), Crown Bioscience and Xentech. Broad incumbents are The Jackson Laboratory and Charles River Laboratories.
Does Xenopat have an API?
No public API is recorded for Xenopat.
What industry is Xenopat in?
Xenopat's product category is Preclinical Oncology Research Services. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy), with a secondary code of HLAIALAC, Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology). Its NAICS code is 621511 and its SIC code is 8731.